IKS012 / Iksuda Therap - LARVOL DELTA

IKS012, a novel ADC design with favorable efficacy and safety for treatment of Folate Receptor Alpha-positive cancers (EORTC-NCI-AACR 2024) - "In the IGROV-1 model, IKS012 showed improved efficacy over MORAb-202, an eribulin ADC with a cathepsin cleavable linker...In the OVCAR-3 model, a single dose of 5 mg/kg IKS012 induced 75% TGI on day 35 in comparison to 42% and 68% TGI for the Elahere analogue and MORAb-202, respectively... The IKS012 ADC design with stable PermaLink® conjugation and the selective glucuronide trigger confers a favorable preclinical anti-tumor activity and safety profile. Our findings support the clinical development of IKS012 for the treatment of FRα-positive solid cancers."

Clinical • Breast Cancer • Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CTSB • CTSC • FOLR1

Iksuda Therapeutics Closes $47 Million Financing Round (Businesswire) - “Iksuda Therapeutics….announced it has completed a US $47 million (circa GB £34 million) financing round…The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform technologies…The investment will enable progression of IKS03 to first-in-human phase 1 clinical trials. It will also be used to accelerate the Company’s earlier-stage programmes including IKS04 and IKS012 to IND filing.”

Financing • Oncology